Shire Plc, the acquisition-oriented specialty pharma company, reported a 6.6% rise in revenue to $6.4 billion for 2015 and a 16.4% decline in operating profit to $1.4 billion using US GAAP. On a non-GAAP basis it reported an 11% rise in both revenue and operating income.
